TLDR
- GlucoTrack stock jumped about 118% in premarket trading to $4.42.
- The move followed news that subsidiary Lōkahi Therapeutics signed its first outside fee-for-service partnership.
- Innovate GBM, a glioblastoma research nonprofit, hired two of Lōkahi’s ai² PIPELINE teams to find licensable brain tumor assets.
- GlucoTrack also issued a post-merger strategic update, splitting focus between glucose monitoring and Lōkahi’s drug pipeline.
- LT-100, an osteoarthritis biologic, remains the company’s top near-term clinical priority.
GlucoTrack (GCTK) stock spiked roughly 118% in premarket trading on Thursday, hitting $4.42. The rally came after the company’s subsidiary, Lōkahi Therapeutics, landed its first external fee-for-service deal.
Innovate GBM, a nonprofit focused on glioblastoma research, engaged two of Lōkahi’s ai² PIPELINE project teams. The teams will work to identify brain tumor therapeutic assets that could be licensed and developed further.
This marks a milestone for Lōkahi. It’s the first outside organization to use the company’s asset-identification process, which runs through 14 university partnerships.
The premarket surge wasn’t isolated. GlucoTrack traded as one of the biggest movers on a list that included names like Digital Currency X Technology and Greenland Mines.
Post-Merger Update
The partnership news landed the same day GlucoTrack gave investors a broader look at its strategy. CEO Erik Emerson laid out how the company plans to operate following its July 14 business combination.
Glucotrack Technologies, the original diabetes-focused arm, stays a wholly owned subsidiary. It will keep working on continuous glucose monitoring.
Meanwhile, the parent company’s capital and core operations now flow toward Lōkahi’s therapeutic asset platform. The model centers on acquiring clinical-stage drug assets cheaply, developing them with discipline, and monetizing them through licensing.
LT-100 is the standout program right now. It’s a biologic aimed at treating osteoarthritis knee pain.
A new clinical study protocol is under regulatory review. The plan is to test a once-weekly subcutaneous injection against an older intradermal regimen.
Management said it’s building out regulatory, clinical operations, and manufacturing capabilities. The goal is to support LT-100 through its next development phase.
The ai² Platform Expansion
Emerson also detailed growth plans for the company’s ai² platform. Its Pipeline engine screens thousands of shelved late-stage pharmaceutical programs through university and industry connections.
That screening process has already surfaced dozens of potential assets. Several are now in early business development talks.
Two other pieces round out the platform: ai² Talent and ai² Accelerator. These are meant to develop industry talent and support new ventures, including one called Qare.
The overall strategy is a repeatable cycle: discover assets, advance them, then monetize them. Management framed this as a way to create multiple paths to future value.
Not everyone is convinced the story is strong yet. According to Spark, TipRanks’ AI analyst, GCTK carries an Underperform rating.
That score reflects weak financials, including no revenue and large ongoing losses. Cash burn has also worsened recently.
Technicals aren’t helping either. Spark noted the price sits well below key moving averages, with a negative MACD reading.
Valuation support is limited too, given the losses and lack of dividend data. Corporate events were described as mixed, with improved funding flexibility offset by rising dilution.
GlucoTrack trades on the Nasdaq under GCTK. Average trading volume sits at 767,577, and current market cap is $1.84 million.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
